Senores Pharmaceuticals Limited has disclosed the creation of a pledge by its promoter group entity Espee Therapeutics LLP on 4,00,000 equity shares. The pledge was created under the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, and reported to both BSE and NSE on February 17, 2026.

Pledge Details

The pledge creation involves specific financial and operational parameters that demonstrate the structured nature of the transaction.

Promoter Group Holdings

Espee Therapeutics LLP holds a total of 4,95,000 equity shares in Senores Pharmaceuticals Limited, representing 1.0748% of the company's total share capital. The pledged shares constitute a significant portion of the entity's total holding in the company.

Regulatory Compliance

The disclosure was made pursuant to Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The company secretary Vinay Kumar Mishra (ICSI Membership No.: F11464) submitted the disclosure on behalf of Senores Pharmaceuticals Limited, while Swapnil Jatinbhai Shah, Designated Partner (DIN: 05259821), signed the disclosure on behalf of Espee Therapeutics LLP.

Stock Exchange Listing

Senores Pharmaceuticals Limited is listed on both major Indian stock exchanges with the following identifiers:

• BSE Scrip Code: 544319
• NSE Symbol: SENORES

The disclosure ensures transparency and compliance with regulatory requirements for substantial shareholding changes and encumbrance creation by promoter group entities.

Senores Pharmaceuticals Limited has received a disclosure from promoter group entity Renosen Pharmaceuticals Private Limited regarding the release of pledge on 4,00,000 equity shares. The pledge was released on February 13, 2026, and disclosed to the stock exchanges on February 16, 2026, in compliance with SAST Regulations 31(1) and 31(2).

Pledge Release Details

The pledge release transaction involves the complete removal of encumbrance on the shares that were previously pledged as collateral to Bajaj Finance Limited:

Regulatory Compliance and Documentation

The disclosure was submitted to both BSE Limited (Scrip Code: 544319) and National Stock Exchange of India Limited (Symbol: SENORES) as mandated under SAST Regulations. Swapnil Jatinbhai Shah, serving as Director of Renosen Pharmaceuticals Private Limited with DIN 05259821, signed the disclosure documents on February 16, 2026.

Vinay Kumar Mishra, Company Secretary and Compliance Officer (ICSI Membership No.: F11464), submitted the formal disclosure on behalf of Senores Pharmaceuticals Limited to both stock exchanges.

Promoter Holdings Structure

The disclosure reveals the comprehensive shareholding pattern of promoters and promoter group entities in Senores Pharmaceuticals Limited:

Company Information

Renosen Pharmaceuticals Private Limited, formerly known as Senores Lifesciences Pvt. Ltd., holds a total of 27,08,719 shares in Senores Pharmaceuticals Limited, representing 5.88% of the total share capital. The company is registered with CIN U51909GJ2019PTC108258 and operates from Ahmedabad. The released pledge amount of 4,00,000 shares previously constituted encumbrance on the entity's holding, which has now been completely cleared.